Provenge for prostate cancer: what to know

Provenge is a personalised cellular immunotherapy used for selected people with advanced prostate cancer after a specialist review. A sample of immune cells is collected, prepared with a prostate-cancer-related target, and returned by infusion in a planned series of visits. Eligibility depends on cancer behaviour, previous treatment, symptoms, general health, and local availability.

The treatment uses your own immune cells. Blood is collected through a process called leukapheresis, then the prepared cells are infused back into you. The aim is to help the immune system recognise and respond to prostate cancer cells. This is different from surgery, radiotherapy, or medicines that directly slow cancer cells, and it may be considered alongside other parts of a personalised plan.

The collection and infusion require scheduling, monitoring, and a suitable vein or access plan. Common short-term reactions can include fever, chills, tiredness, headache, nausea, or muscle aches. Your team explains which symptoms are expected and how they will monitor you.

Tell the team about medicines, allergies, infections, heart or lung problems, and any difficulty passing urine. Arrange transport if you feel unwell after an infusion and keep your appointment instructions available. Drink and eat according to the team’s guidance, and record fever or new symptoms. Continue prescribed prostate-cancer medicines unless your clinician gives different instructions.

Contact the oncology team for persistent fever, shaking chills, worsening weakness, repeated vomiting, or redness and pain at the collection or infusion site. Seek emergency help for trouble breathing, facial or throat swelling, chest pain, fainting, severe confusion, or inability to pass urine. These symptoms need prompt assessment rather than waiting for the next appointment.

Ask why Provenge is being considered now, how cell collection and infusion are scheduled, which reactions require a call, and how response will be followed. Ask how it fits with hormone treatment, radiotherapy, targeted radioisotope therapy, surgery, or bone-strengthening therapy.